Trial Profile
Contribution of Immuno - PET préciblée the bispecific antibody with anti- CEA x anti -HSG peptide IMP and TF2 -288 labeled with Gallium -68 For Imaging of Patients Potentially Candidates An excisional surgery and / or thermoablation One or several of local metastases at diagnosis or relapse When Colo- rectal Cancers (CCR) Expressing Carcino antigen ( CEA) : Comparison with Conventional Review [Apport de l'Immuno-TEP préciblée Avec l'Anticorps bispécifique Anti-ACE x Anti-HSG TF2 et le Peptide IMP-288 marqué au Gallium-68 Pour l'Imagerie Des Patients Potentiellement Candidats à Une Chirurgie d'exérèse et/ou Thermoablation Locale d'Une ou Plusieurs métastases, au Diagnostic ou Lors de la Rechute de Cancers Colo-rectaux (CCR) Exprimant l'antigène Carcino-embryonnaire (ACE): Comparaison au Bilan Conventionnel]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Gallium-68-IMP-288 (Primary) ; TF 2 (Primary)
- Indications Colorectal cancer
- Focus Diagnostic use
- Acronyms iTEP Colon
- 17 Jan 2017 Status changed from recruiting to completed.
- 24 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 30 Oct 2015 New trial record